Ir para o conteúdo principal

United States Últimas notícias

Todas as matérias desta categoria, das mais recentes às mais antigas.

Grafa
Auto and cars

Tesla deliveries miss estimates as massive production gap signals waning demand

Tesla (NASDAQ:TSLA) reported first-quarter delivery numbers that fell short of Wall Street expectations, raising fresh concerns about a widening gap between the electric vehicle maker's manufacturing pace and global consumer appetite.

Leia mais: Tesla deliveries miss estimates as massive production gap signals waning demand
Grafa
Technology

Innovative Aerosystems expands general aviation footprint with Honeywell Avionics deal

Innovative Aerosystems (NASDAQ:ISSC) has reached an agreement with Honeywell International (NASDAQ:HON) to acquire key assets and intellectual property for select legacy avionics lines, a move that deepens the company’s reach into the global general aviation market.

Leia mais: Innovative Aerosystems expands general aviation footprint with Honeywell Avionics deal
Grafa

Merck’s Keytruda gains EU approval as first PD-1 therapy for hard-to-treat ovarian cancer

Merck (NYSE:MRK) has secured a landmark regulatory approval in the European Union for its blockbuster immunotherapy Keytruda, marking the region’s first PD-1 inhibitor authorized to treat a particularly aggressive form of ovarian cancer.

Leia mais: Merck’s Keytruda gains EU approval as first PD-1 therapy for hard-to-treat ovarian cancer
Grafa

Adagene masked CTLA-4 shows breakthrough potential in colorectal cancer

Adagene (NASDAQ:ADAG) reported updated clinical data for its lead "SAFEbody" candidate, muzastotug, revealing a significant dose-dependent response in patients with treatment-resistant colorectal cancer—a population that has traditionally been unresponsive to immunotherapy.

Leia mais: Adagene masked CTLA-4 shows breakthrough potential in colorectal cancer
Grafa
Mining

Namib Minerals posts EBITDA growth as strategic expansions move toward 2026 milestones

Namib Minerals (NASDAQ:NAMM) reported a resilient fiscal 2025 performance, characterized by rising profitability and steady progress on its multi-asset growth strategy in Zimbabwe, despite a slight dip in annual gold production.

Leia mais: Namib Minerals posts EBITDA growth as strategic expansions move toward 2026 milestones
Grafa
Agriculture

ScottsMiracle-Gro shields margins with domestic sourcing as 2026 targets reaffirmed

ScottsMiracle-Gro (NYSE:SMG) has reaffirmed its fiscal 2026 financial guidance, signaling confidence in its margin recovery plan by highlighting a supply chain largely insulated from international volatility and inflationary spikes.

Leia mais: ScottsMiracle-Gro shields margins with domestic sourcing as 2026 targets reaffirmed
Grafa

Adagene and Incyte form alliance to target treatment-resistant colorectal cancer

Adagene (NASDAQ:ADAG) and Incyte (NASDAQ:INCY) have entered into a clinical trial collaboration to evaluate a potent combination of immunotherapy agents in patients with microsatellite stable colorectal cancer (MSS CRC), a disease state notoriously resistant to standard immune checkpoint inhibitors.

Leia mais: Adagene and Incyte form alliance to target treatment-resistant colorectal cancer
Grafa

AstraZeneca immunotherapy combo delays liver cancer progression in Phase III study

AstraZeneca (NASDAQ:AZN) announced positive high-level results from its EMERALD-3 Phase III trial, demonstrating that a novel combination of immunotherapies and targeted treatment significantly improved outcomes for patients with the most common form of liver cancer.

Leia mais: AstraZeneca immunotherapy combo delays liver cancer progression in Phase III study
Grafa

Merck accelerates EyeBio integration with pivotal trial for dual-action retina therapy

Merck (NYSE:MRK) has officially moved its lead ophthalmology candidate into late-stage development, initiating a pivotal Phase 2b/3 trial for MK-8748 just two years after the pharmaceutical giant’s $3 billion acquisition of EyeBio.

Leia mais: Merck accelerates EyeBio integration with pivotal trial for dual-action retina therapy